Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390



Status:Archived
Conditions:Hepatitis, Hematology
Therapuetic Areas:Hematology, Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:September 2009
End Date:August 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)


The purpose of this study is to test the safety and tolerability of eltrombopag when used to
increase and maintain platelet count. Platelet count to be maintained at a level sufficient
to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose
reductions, and to avoid permanent discontinuation of antiviral therapy.



We found this trial at
4
sites
West Virginia University Hospitals Inc.
1 Medical Center Drive
Morgantown, West Virginia 26506
304-598-4800
West Virginia University Hospitals Inc. WVU Healthcare is two corporations, University Health Associates and WVU...
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
GSK Investigational Site
Honolulu, Hawaii 96813
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
GSK Investigational Site
Knoxville, Tennessee 37916
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
GSK Investigational Site
New Haven, Connecticut 06520
?
mi
from
New Haven, CT
Click here to add this to my saved trials